- Home
- NKTX
NKTX
Nkarta Inc.
as 07-26-2024 4:00pm EST
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 467.9M | IPO Year: | 2020 |
| Target Price: | $17.50 | AVG Volume (30 days): | 923.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.28 - $16.24 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Nkarta Inc. (NKTX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| HASTINGS PAUL J | NKTX | Chief Executive Officer | Jun 18 '24 | Sell | $5.60 | 1,770 | $9,912.00 | 240,737 | SEC Form 4 |
| Shook David | NKTX | Chief Medical Officer | Jun 18 '24 | Sell | $5.60 | 456 | $2,553.60 | 116,524 | SEC Form 4 |
| Trager James | NKTX | Chief Scientific Officer | Jun 18 '24 | Sell | $5.60 | 456 | $2,553.60 | 150,959 | SEC Form 4 |
| Hager Alicia J. | NKTX | Chief Legal Officer | Jun 18 '24 | Sell | $5.60 | 727 | $4,071.20 | 107,215 | SEC Form 4 |
| Brandenberger Ralph | NKTX | Chief Technical Officer | Jun 18 '24 | Sell | $5.60 | 229 | $1,282.40 | 79,743 | SEC Form 4 |
| RA CAPITAL MANAGEMENT, L.P. | NKTX | Director10% Owner | Mar 27 '24 | Buy | $10.00 | 3,000,000 | $30,000,000.00 | 10,050,818 | SEC Form 4 |
| George Simeon | NKTX | Director | Mar 27 '24 | Buy | $10.00 | 1,548,341 | $15,483,410.00 | 1,548,341 | SEC Form 4 |
| George Simeon | NKTX | Director | Mar 27 '24 | Buy | $10.00 | 451,659 | $4,516,590.00 | 451,659 | SEC Form 4 |
| Brandenberger Ralph | NKTX | Chief Technical Officer | Mar 1 '24 | Sell | $12.51 | 8,367 | $104,671.17 | 79,972 | SEC Form 4 |
| Trager James | NKTX | Chief Scientific Officer | Feb 12 '24 | Sell | $12.00 | 4,143 | $49,716.00 | 149,415 | SEC Form 4 |
| Brandenberger Ralph | NKTX | Chief Technical Officer | Jan 16 '24 | Sell | $8.74 | 2,512 | $21,954.88 | 81,576 | SEC Form 4 |
| Trager James | NKTX | Chief Scientific Officer | Jan 16 '24 | Sell | $8.74 | 4,560 | $39,854.40 | 153,558 | SEC Form 4 |
| HASTINGS PAUL J | NKTX | Chief Executive Officer | Jan 16 '24 | Sell | $8.74 | 9,697 | $84,751.78 | 390,507 | SEC Form 4 |
| Shook David | NKTX | Chief Medical Officer | Jan 16 '24 | Sell | $8.74 | 3,552 | $31,044.48 | 114,980 | SEC Form 4 |
| Hager Alicia J. | NKTX | Chief Legal Officer | Jan 16 '24 | Sell | $8.74 | 4,554 | $39,801.96 | 107,942 | SEC Form 4 |
Latest Nkarta Inc. News
NKTX Breaking Stock News: Dive into NKTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus
MT Newswires
10 days ago
Nkarta Shares Rise After Nadir Mahmood Named as President
GlobeNewswire
11 days ago
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
Zacks
16 days ago
Nkarta (NKTX) Upgraded to Buy: Here's What You Should Know
MT Newswires
a month ago
Nkarta Initiates Trial of Cell Therapy to Treat Lupus Nephritis; FDA Clears Second Application
GlobeNewswire
a month ago
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
GlobeNewswire
a month ago
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
The Telegraph
2 months ago
Italian energy company targets Britain for fleet of 20 mini-nukes
Compare NKTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NKTX Nkarta Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.